Skip to Content

Optiray 350 (ioversol) Disease Interactions

There are 7 disease interactions with Optiray 350 (ioversol):


Iodinated radiopaque contrast agents (applies to Optiray 350) hyperthyroidism

Major Potential Hazard, Moderate plausibility.

Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium. Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.


Radiopaque contrast agents (applies to Optiray 350) pheochromocytoma

Major Potential Hazard, Moderate plausibility.

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.


Contrast agents (applies to Optiray 350) sickle cell disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sickle Cell Anemia

Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially. Caution is advised.


Iodinated contrast agents (applies to Optiray 350) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. Caution is advised when using these agents in patients with this condition.


Iodinated contrast media (applies to Optiray 350) asthma/allergies

Moderate Potential Hazard, Moderate plausibility.

Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Caution is advised on these patients. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.


Ioversol (applies to Optiray 350) acute renal failure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Diabetes Mellitus, Multiple Myeloma, Congestive Heart Failure

Acute kidney injury, including renal failure, may occur after ioversol administration. Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications. The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.


Ioversol (applies to Optiray 350) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Congestive Heart Failure, Liver Disease

Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock. Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor. Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease. Caution should be used when using ioversol in these patients and the lowest dose possible should be used.

Optiray 350 (ioversol) drug interactions

There are 142 drug interactions with Optiray 350 (ioversol)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.